Company registration number 13740530 (England and Wales)
ABCLONAL UK LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
ABCLONAL UK LIMITED
CONTENTS
Page
Balance sheet
1
Notes to the financial statements
2 - 8
ABCLONAL UK LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2024
31 December 2024
- 1 -
2024
2023
Notes
£
£
FIXED ASSETS
Tangible assets
4
-
0
22,985
CURRENT ASSETS
Stocks
-
27,461
Debtors
5
27,464
31,781
Cash at bank and in hand
846
108,332
28,310
167,574
CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
6
(333,718)
(505,616)
NET CURRENT LIABILITIES
(305,408)
(338,042)
NET LIABILITIES
(305,408)
(315,057)
CAPITAL AND RESERVES
Called up share capital
50,000
50,000
Share premium account
150,000
150,000
Profit and loss reserves
(505,408)
(515,057)
TOTAL EQUITY
(305,408)
(315,057)

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 26 September 2025 and are signed on its behalf by:
Mr J Zong
Director
Company registration number 13740530 (England and Wales)
ABCLONAL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2024
- 2 -
1
ACCOUNTING POLICIES
Company information

Abclonal UK Limited is a private company limited by shares incorporated in England and Wales. The registered office is 29 Cherry Grove, Sketty, SWANSEA, SA2 8AT.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The company's ultimate parent undertaking, Wuhan ABclonal Biotechnology Co, Ltd includes the company in its consolidated financial statements.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary a mounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

These financial statements for the year ended 31 December 2024 are the first financial statements of Abclonal UK Limited prepared in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland. The date of transition to FRS 102 was 1 January 2023. The reported financial position and financial performance for the previous period are not affected by the transition to FRS 102.

1.2
Going concern

The company has been able to finance its operations due to financing and support from its parent company. In January 2024 the decision was made to cease trading with effect from 31 March 2024, with remaining assets sold and stocks transferred to related companies. Therefore the company is no longer a going concern and the accounts are not prepared on this basis. Impairment reviews have been undertaken at the balance sheet date to reflect fixed and current assets at recoverable amount, where lower than historical cost or net book value. Creditors classified as falling due after more than one year have been reclassified as current liabilities where appropriate.true

1.3
Turnover

Revenue comprises sales of goods or services provided to customers net of value added tax and other sales taxes, less an appropriate deduction for actual and expected returns and discounts. Revenue is recognised when performance obligations are satisfied and the control of goods or services is transferred to the buyer. Where the performance obligation is satisfied over time, revenue is recognised in accordance with its progress towards complete satisfaction of that performance obligation.

When cash inflows are deferred and represent a financing arrangement, the promised consideration is adjusted for the effects of the time value of money, which is recognised as interest income.

ABCLONAL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
ACCOUNTING POLICIES
(Continued)
- 3 -

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold land and buildings
over the lease term
Plant and equipment
20% straight line
Equipments
33% straight line
Motor vehicles
25% straight line

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

ABCLONAL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
ACCOUNTING POLICIES
(Continued)
- 4 -
1.6
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

1.7
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.8
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

ABCLONAL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
1
ACCOUNTING POLICIES
(Continued)
- 5 -
Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future paymen ts discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. A m ounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.9
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.10
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.11
Leases
As lessee

Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessees. All other leases are classified as operating leases.

Assets held under finance leases are recognised as assets at the lower of the assets fair value at the date of inception and the present value of the minimum lease payments. The related liability is included in the balance sheet as a finance lease obligation. Lease payments are treated as consisting of capital and interest elements. The interest is charged to profit or loss so as to produce a constant periodic rate of interest on the remaining balance of the liability.

ABCLONAL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 6 -
2
JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

In the application of the company’s accounting policies, the director is required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

Key sources of estimation uncertainty

The estimates and assumptions which have a significant risk of causing a material adjustment to the carrying amount of assets and liabilities are as follows.

Right of use assets

The interest rate used in Right-of-Use assets calculations - all assets we're disposed of at the balance sheet date.

3
EMPLOYEES

The average monthly number of persons (including directors) employed by the company during the year was:

2024
2023
Number
Number
Total
1
5
ABCLONAL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 7 -
4
TANGIBLE FIXED ASSETS
Land and buildings
Plant and machinery etc
Total
£
£
£
Cost
At 1 January 2024
19,040
32,696
51,736
Disposals
(19,040)
(32,696)
(51,736)
At 31 December 2024
-
0
-
0
-
0
Depreciation and impairment
At 1 January 2024
13,557
15,194
28,751
Depreciation charged in the year
5,483
-
0
5,483
Eliminated in respect of disposals
(19,040)
(15,194)
(34,234)
At 31 December 2024
-
0
-
0
-
0
Carrying amount
At 31 December 2024
-
0
-
0
-
0
At 31 December 2023
5,483
17,502
22,985
5
DEBTORS
2024
2023
Amounts falling due within one year:
£
£
Trade debtors
-
0
28,766
Amounts owed by group undertakings
27,461
-
0
Other debtors
3
3,015
27,464
31,781
ABCLONAL UK LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2024
- 8 -
6
CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024
2023
£
£
Bank loans and overdrafts
21
-
0
Amounts owed to group undertakings
333,697
455,652
Taxation and social security
-
0
12,311
Other creditors
-
0
37,653
333,718
505,616
7
AUDIT REPORT INFORMATION

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report is unqualified and includes the following:

Senior Statutory Auditor:
Huw Sheppard
Statutory Auditor:
Kilsby & Williams LLP
Date of audit report:
15 October 2025
8
PARENT COMPANY

The company's immediate and ultimate parent company is Wuhan ABclonal Biotechnology Co. Ltd, a company incorporated in China which is the parent company of the smallest and largest group into which the results of the company are consolidated. This company's registered office address is Building 4, Precision Medicine Industry, Base 4, No.9 Gaokeyuan Road, Wuhan, China.

The director considers the controlling party to be the ultimate parent undertaking, Wuhan ABclonal Buotechnology Co. Ltd.

2024-12-31 2024-01-01 false false false 15 October 2025 CCH Software CCH Accounts Production 2025.200 The principal activity of the company is research and experimental development on biotechnology.
Mr X Peng Mr J Zong Mrs J Zhang 13740530 2024-01-01 2024-12-31 13740530 2024-12-31 13740530 2023-12-31 13740530 core:LandBuildings 2024-12-31 13740530 core:OtherPropertyPlantEquipment 2024-12-31 13740530 core:LandBuildings 2023-12-31 13740530 core:OtherPropertyPlantEquipment 2023-12-31 13740530 core:CurrentFinancialInstruments core:WithinOneYear 2024-12-31 13740530 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 13740530 core:ShareCapital 2024-12-31 13740530 core:ShareCapital 2023-12-31 13740530 core:SharePremium 2024-12-31 13740530 core:SharePremium 2023-12-31 13740530 core:RetainedEarningsAccumulatedLosses 2024-12-31 13740530 core:RetainedEarningsAccumulatedLosses 2023-12-31 13740530 bus:Director2 2024-01-01 2024-12-31 13740530 core:LandBuildings core:LongLeaseholdAssets 2024-01-01 2024-12-31 13740530 core:PlantMachinery 2024-01-01 2024-12-31 13740530 core:ComputerEquipment 2024-01-01 2024-12-31 13740530 core:MotorVehicles 2024-01-01 2024-12-31 13740530 2023-01-01 2023-12-31 13740530 core:LandBuildings 2023-12-31 13740530 core:OtherPropertyPlantEquipment 2023-12-31 13740530 2023-12-31 13740530 core:LandBuildings 2024-01-01 2024-12-31 13740530 core:OtherPropertyPlantEquipment 2024-01-01 2024-12-31 13740530 core:CurrentFinancialInstruments 2024-12-31 13740530 core:CurrentFinancialInstruments 2023-12-31 13740530 core:WithinOneYear 2024-12-31 13740530 core:WithinOneYear 2023-12-31 13740530 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 13740530 bus:SmallCompaniesRegimeForAccounts 2024-01-01 2024-12-31 13740530 bus:FRS102 2024-01-01 2024-12-31 13740530 bus:Audited 2024-01-01 2024-12-31 13740530 bus:Director1 2024-01-01 2024-12-31 13740530 bus:Director3 2024-01-01 2024-12-31 13740530 bus:FullAccounts 2024-01-01 2024-12-31 xbrli:pure xbrli:shares iso4217:GBP